FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3116765306> ?p ?o ?g. }

• W3116765306 endingPage "68" @default.
• W3116765306 startingPage "59" @default.
• W3116765306 abstract "Targeted agents, such as antiangiogenic drugs (e.g., bevacizumab) and poly(ADP-ribose) polymerase inhibitors (e.g., rucaparib), have been shown to improve outcomes in patients with newly diagnosed or recurrent ovarian cancer. Evidence suggests that combinations of these two classes of targeted agents may result in synergistic antitumor activity.The phase I portion of MITO 25 was designed to determine the maximum tolerated dose, pharmacokinetics, and the safety profile of rucaparib when administered in combination with bevacizumab as maintenance treatment for patients with high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer.This was a single-arm, phase I dose-escalation study. Cohorts of three patients were recruited to receive increasing rucaparib doses of 400 mg, 500 mg, or 600 mg twice daily for 28 days. Bevacizumab 15 mg/kg was administered at day 1 every 21 days.We enrolled nine patients. Two patients in the rucaparib 600-mg group had four grade 3 treatment-emergent adverse events: increased in alanine aminotransferase and aspartate aminotransferase levels, depression, and hallucinations. These were deemed to be dose-limiting toxicities related to rucaparib. Because these dose-limiting toxicities occurred in the 600-mg group and affected more than one in three patients, the maximum tolerated dose for rucaparib was considered 500 mg twice daily when combined with bevacizumab 15 mg/kg at day 1 every 21 days. There were no new safety concerns from using the combination. No substantial difference in pharmacokinetic parameters was found between the cohorts or in the pharmacokinetic profiles of rucaparib administered alone or with bevacizumab with respect to historical controls.The maximum tolerated dose of rucaparib is 500 mg twice daily when co-administered with bevacizumab. The plasma concentration-time profiles of rucaparib in combination with bevacizumab suggest no pharmacokinetic interactions between the drugs. The randomized phase II portion of MITO 25 will further investigate rucaparib maintenance treatment with or without bevacizumab in patients with newly diagnosed stage III-IV ovarian cancer who responded to carboplatin-paclitaxel chemotherapy with or without bevacizumab.ClinicalTrials.gov identifier NCT03462212; registered March 2018." @default.
• W3116765306 created "2021-01-05" @default.
• W3116765306 creator A5000568505 @default.
• W3116765306 creator A5002415873 @default.
• W3116765306 creator A5002916569 @default.
• W3116765306 creator A5009935310 @default.
• W3116765306 creator A5011135357 @default.
• W3116765306 creator A5025221164 @default.
• W3116765306 creator A5029537523 @default.
• W3116765306 creator A5034996924 @default.
• W3116765306 creator A5055703421 @default.
• W3116765306 creator A5055791813 @default.
• W3116765306 creator A5056006346 @default.
• W3116765306 creator A5061939825 @default.
• W3116765306 creator A5077698155 @default.
• W3116765306 creator A5082667528 @default.
• W3116765306 date "2020-12-28" @default.
• W3116765306 modified "2023-09-26" @default.
• W3116765306 title "Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile" @default.
• W3116765306 cites W1603230122 @default.
• W3116765306 cites W1793338775 @default.
• W3116765306 cites W1976839993 @default.
• W3116765306 cites W1998258610 @default.
• W3116765306 cites W2002158391 @default.
• W3116765306 cites W2009007206 @default.
• W3116765306 cites W2098737737 @default.
• W3116765306 cites W2105623825 @default.
• W3116765306 cites W2112241575 @default.
• W3116765306 cites W2113467627 @default.
• W3116765306 cites W2136689090 @default.
• W3116765306 cites W2142658272 @default.
• W3116765306 cites W2151509048 @default.
• W3116765306 cites W2160466424 @default.
• W3116765306 cites W2528228811 @default.
• W3116765306 cites W2557666746 @default.
• W3116765306 cites W2593067736 @default.
• W3116765306 cites W2605456582 @default.
• W3116765306 cites W2737389832 @default.
• W3116765306 cites W2737586869 @default.
• W3116765306 cites W2740197154 @default.
• W3116765306 cites W2754327139 @default.
• W3116765306 cites W2799576051 @default.
• W3116765306 cites W2802074519 @default.
• W3116765306 cites W2803203200 @default.
• W3116765306 cites W2805080267 @default.
• W3116765306 cites W2906986535 @default.
• W3116765306 cites W2964531484 @default.
• W3116765306 cites W2984886575 @default.
• W3116765306 cites W2994977341 @default.
• W3116765306 cites W3089236216 @default.
• W3116765306 doi "https://doi.org/10.1007/s11523-020-00780-4" @default.
• W3116765306 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7810645" @default.
• W3116765306 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33369704" @default.
• W3116765306 hasPublicationYear "2020" @default.
• W3116765306 type Work @default.
• W3116765306 sameAs 3116765306 @default.
• W3116765306 citedByCount "9" @default.
• W3116765306 countsByYear W31167653062021 @default.
• W3116765306 countsByYear W31167653062022 @default.
• W3116765306 countsByYear W31167653062023 @default.
• W3116765306 crossrefType "journal-article" @default.
• W3116765306 hasAuthorship W3116765306A5000568505 @default.
• W3116765306 hasAuthorship W3116765306A5002415873 @default.
• W3116765306 hasAuthorship W3116765306A5002916569 @default.
• W3116765306 hasAuthorship W3116765306A5009935310 @default.
• W3116765306 hasAuthorship W3116765306A5011135357 @default.
• W3116765306 hasAuthorship W3116765306A5025221164 @default.
• W3116765306 hasAuthorship W3116765306A5029537523 @default.
• W3116765306 hasAuthorship W3116765306A5034996924 @default.
• W3116765306 hasAuthorship W3116765306A5055703421 @default.
• W3116765306 hasAuthorship W3116765306A5055791813 @default.
• W3116765306 hasAuthorship W3116765306A5056006346 @default.
• W3116765306 hasAuthorship W3116765306A5061939825 @default.
• W3116765306 hasAuthorship W3116765306A5077698155 @default.
• W3116765306 hasAuthorship W3116765306A5082667528 @default.
• W3116765306 hasBestOaLocation W31167653061 @default.
• W3116765306 hasConcept C112705442 @default.
• W3116765306 hasConcept C121608353 @default.
• W3116765306 hasConcept C126322002 @default.
• W3116765306 hasConcept C143998085 @default.
• W3116765306 hasConcept C197934379 @default.
• W3116765306 hasConcept C2776694085 @default.
• W3116765306 hasConcept C2777249960 @default.
• W3116765306 hasConcept C2777802072 @default.
• W3116765306 hasConcept C2780427987 @default.
• W3116765306 hasConcept C71924100 @default.
• W3116765306 hasConcept C90924648 @default.
• W3116765306 hasConcept C98274493 @default.
• W3116765306 hasConceptScore W3116765306C112705442 @default.
• W3116765306 hasConceptScore W3116765306C121608353 @default.
• W3116765306 hasConceptScore W3116765306C126322002 @default.
• W3116765306 hasConceptScore W3116765306C143998085 @default.
• W3116765306 hasConceptScore W3116765306C197934379 @default.
• W3116765306 hasConceptScore W3116765306C2776694085 @default.
• W3116765306 hasConceptScore W3116765306C2777249960 @default.
• W3116765306 hasConceptScore W3116765306C2777802072 @default.
• W3116765306 hasConceptScore W3116765306C2780427987 @default.
• W3116765306 hasConceptScore W3116765306C71924100 @default.

• next